Free tool
FAERS Monitor: Atorvaliq
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 213260 or its brand name (Atorvaliq, Atorvastatin Calcium). Reports on generic versions are filed under their own applications.
Reports
21
Serious
12
57% of reports
Hospitalization
5
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use3
- dizziness2
- eye pain2
- headache2
- hypervolaemia2
- pain2
- peripheral swelling2
- product dose omission issue2
- pruritus2
- vision blurred2
- weight decreased2
- abdominal pain1
- abdominal pain upper1
- accidental overdose1
- acute kidney injury1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 11 |
| 2026 | 6 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,138 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hypervolaemia | 2 | 405.5 | 108.5 | 453 |
| eye pain | 2 | 35.5 | 9.5 | 37 |
| accidental overdose | 1 | 27.4 | 4.0 | 6 |
| vision blurred | 2 | 14.6 | 3.9 | 14 |
| peripheral swelling | 2 | 13.0 | 3.5 | 12 |
| weight decreased | 2 | 7.2 | 1.9 | 5 |
| product dose omission issue | 2 | 6.8 | 1.8 | 5 |
| acute kidney injury | 1 | 6.5 | 1.0 | 1 |
| pruritus | 2 | 5.2 | 1.4 | 3 |
| abdominal pain upper | 1 | 4.9 | 0.7 | 0 |
| abdominal pain | 1 | 4.3 | 0.6 | 0 |
| dizziness | 2 | 4.0 | 1.1 | 2 |
| off label use | 3 | 3.4 | 1.2 | 3 |
| pain | 2 | 3.3 | 0.9 | 1 |
| headache | 2 | 3.2 | 0.9 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.